Spots Global Cancer Trial Database for invasive
Every month we try and update this database with for invasive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | NCT02852564 | Bladder Cancer | Ethacrynic Acid | 18 Years - | University of Kansas Medical Center | |
| Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer | NCT02459912 | Prostate Cancer | Unilateral Nerv... Precise Cryoabl... | 40 Years - 69 Years | NYU Langone Health | |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder | NCT02202772 | Urothelial Carc... | Cabazitaxel Gemcitabine Cisplatin | 18 Years - | Columbia University | |
| Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer | NCT02459912 | Prostate Cancer | Unilateral Nerv... Precise Cryoabl... | 40 Years - 69 Years | NYU Langone Health | |
| Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | NCT05774990 | Leukemia, Myelo... Acute Lymphobla... | - 17 Years | University of Southern Denmark | ||
| Dose Dense MVAC for Muscle Invasive Bladder Cancer | NCT01031420 | Muscle Invasive... High Risk Uroth... | single arm dose... | 18 Years - | Fox Chase Cancer Center | |
| Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer | NCT02459912 | Prostate Cancer | Unilateral Nerv... Precise Cryoabl... | 40 Years - 69 Years | NYU Langone Health | |
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | NCT03412643 | HER2-negative B... | Doxorubicin Cyclophosphamid... Weekly Paclitax... Trastuzumab Pertuzumab Celcuity CELx H... | 18 Years - | NSABP Foundation Inc | |
| "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " | NCT02530424 | Breast Neoplasm... | Trastuzumab Pertuzumab Palbociclib Fulvestrant | 18 Years - | Fondazione Michelangelo | |
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | NCT03412643 | HER2-negative B... | Doxorubicin Cyclophosphamid... Weekly Paclitax... Trastuzumab Pertuzumab Celcuity CELx H... | 18 Years - | NSABP Foundation Inc | |
| Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | NCT05774990 | Leukemia, Myelo... Acute Lymphobla... | - 17 Years | University of Southern Denmark | ||
| Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | NCT02852564 | Bladder Cancer | Ethacrynic Acid | 18 Years - | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
